난치성 통풍 치료용 인터루킨 억제제 시장 : 세계 예측(2026-2032년)

The Interleukin Inhibitors for the Treatment of Refractory Gout Market is projected to grow by USD 3.08 billion at a CAGR of 12.11% by 2032.

Interleukin Inhibitors Address an Unmet Need in Refractory Gout

Interleukin inhibitors are targeted anti-inflammatory therapies being evaluated or used for patients with refractory gout, particularly when conventional urate-lowering and anti-inflammatory approaches are inadequate, poorly tolerated, or unsuitable. Their clinical rationale centers on suppressing interleukin-mediated inflammation associated with acute gout flares and persistent disease activity. Adoption is shaped by treatment eligibility, evidence standards, safety monitoring, reimbursement, and access to specialist care.

Treatment Pathways Are Shifting Toward Targeted, Specialist-Led Care

The treatment landscape is moving from episodic flare management toward integrated control of urate burden, inflammation, comorbidities, and adherence. Targeted interleukin inhibition is most relevant where disease remains difficult to control despite established interventions. Important shifts include greater emphasis on guideline-concordant care, earlier referral to rheumatology, structured risk assessment, infection screening, and clearer differentiation between acute rescue treatment and longer-term disease management.

Artificial Intelligence Can Improve Identification, Monitoring, and Evidence Generation

Artificial intelligence may support this field by identifying patients with recurrent or refractory disease from clinical records, improving flare documentation, and helping clinicians recognize patterns across laboratory results, imaging, medication histories, and comorbidities. Predictive tools could assist with treatment-risk stratification and follow-up prioritization, but their value depends on representative data, transparent validation, privacy safeguards, and clinician oversight. AI should complement-not replace-clinical judgment and established safety monitoring.

Regional Access Depends on Specialist Capacity and Health-System Readiness

In North America, access is influenced by specialist prescribing, prior authorization, payer criteria, and monitoring infrastructure. Europe combines evidence-based guideline implementation with substantial variation in national reimbursement and referral pathways. Asia-Pacific includes highly developed specialty systems alongside settings where diagnosis, biologic access, and continuity of care are more limited. Latin America faces uneven availability of rheumatology services, diagnostics, and reimbursement. In the Middle East, concentrated tertiary-care capacity coexists with differences in coverage and referral systems. Africa's priorities include earlier diagnosis, affordable access, supply reliability, and expansion of specialist and laboratory capacity.

Economic Blocs Shape Regulation, Procurement, and Clinical Adoption

ASEAN markets differ in regulatory maturity, specialist density, and public-sector access, making country-level implementation important. BRICS members span diverse healthcare financing and manufacturing environments, with access often shaped by public procurement and local regulatory requirements. The European Union benefits from shared scientific and regulatory structures but retains national differences in reimbursement and clinical practice. G7 countries generally have stronger specialty infrastructure and pharmacovigilance systems, while affordability and payer restrictions remain relevant. NATO members represent varied health systems, but coordinated preparedness and established clinical networks can support standardized safety practices. GCC states often have concentrated specialist services and advanced hospital infrastructure, alongside differences in coverage and purchasing policies.

Country Conditions Determine Patient Access and Clinical Use

Australia and Canada rely on specialist-led pathways within publicly influenced systems, with formulary rules affecting access. Brazil, Mexico, India, and Russia face substantial regional variation in specialist availability, reimbursement, and medicine procurement. China is strengthening specialty care and evidence generation while navigating complex regional implementation. France, Germany, Italy, Spain, and the United Kingdom combine mature rheumatology services with country-specific assessment, reimbursement, and prescribing processes. Japan and South Korea have advanced clinical infrastructure, but approval, reimbursement, and local evidence requirements influence uptake. Across the United States, specialist access, payer authorization, safety monitoring, and high out-of-pocket exposure can materially affect treatment continuity.

Leaders Should Link Evidence, Access, and Safe Implementation

Industry leaders should define the patient population precisely, distinguish refractory disease from undertreatment or nonadherence, and generate evidence relevant to real-world specialist practice. Educational initiatives should support early referral, shared decision-making, infection-risk assessment, and appropriate monitoring. Access strategies should address reimbursement documentation, affordability, cold-chain or administration requirements where applicable, and continuity across care settings. Organizations should also invest in transparent pharmacovigilance, interoperable data, validated digital tools, and region-specific partnerships without overstating clinical benefit beyond the evidence.

Methodology Combines Clinical Evidence With Health-System Assessment

This executive summary is based on a structured assessment of the therapeutic role of interleukin inhibition in refractory gout, with attention to clinical need, treatment pathways, safety considerations, access conditions, and implementation requirements. The analysis organizes insights across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, and considers ASEAN, BRICS, the European Union, G7, GCC, and NATO groupings. Country interpretation covers Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom, and the United States. Conclusions are framed qualitatively and avoid unsupported estimates or projections.

Successful Adoption Requires Targeted Use and Health-System Discipline

Interleukin inhibitors occupy a specialized role in the management of difficult-to-treat gout, where patient selection, safety, and specialist oversight are central. The opportunity for meaningful clinical value depends less on broad use than on appropriate identification of patients whose needs are not met by established care. Sustainable implementation will require credible evidence, equitable access, reliable monitoring, and coordinated action across clinicians, payers, regulators, and healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Product

• 7.1. Introduction
• 7.2. Anakinra
• 7.3. Canakinumab
• 7.4. Rilonacept

8. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Intravenous Injection
• 8.3. Subcutaneous Injection

9. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Dosage Form

• 9.1. Introduction
• 9.2. Pre-Filled Pen
• 9.3. Pre-Filled Syringe
• 9.4. Vial

10. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Treatment Setting

• 10.1. Introduction
• 10.2. Inpatient
• 10.3. Outpatient

11. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Patient Category

• 11.1. Introduction
• 11.2. Adult
• 11.3. Elderly
• 11.4. Pediatric

12. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by End User

• 12.1. Introduction
• 12.2. Homecare Providers
• 12.3. Hospitals
• 12.4. Specialty Clinics
  • 12.4.1. Orthopedic Clinics
  • 12.4.2. Rheumatology Clinics

13. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Distribution Channel

• 13.1. Introduction
• 13.2. Hospital Pharmacies
  • 13.2.1. Centralized Pharmacies
  • 13.2.2. Satellite Pharmacies
• 13.3. Online Pharmacies
• 13.4. Retail Pharmacies

14. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Region

• 14.1. Introduction
• 14.2. Asia-Pacific
• 14.3. North America
• 14.4. Latin America
• 14.5. Europe
• 14.6. Middle East
• 14.7. Africa

15. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Group

• 15.1. Introduction
• 15.2. ASEAN
• 15.3. GCC
• 15.4. European Union
• 15.5. BRICS
• 15.6. G7
• 15.7. NATO

16. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Country

• 16.1. Introduction
• 16.2. United States
• 16.3. Canada
• 16.4. Mexico
• 16.5. Brazil
• 16.6. United Kingdom
• 16.7. Germany
• 16.8. France
• 16.9. Russia
• 16.10. Italy
• 16.11. Spain
• 16.12. China
• 16.13. India
• 16.14. Japan
• 16.15. Australia
• 16.16. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. Market Concentration Analysis, 2025
  • 17.2.1. Concentration Ratio (CR)
  • 17.2.2. Herfindahl Hirschman Index (HHI)
• 17.3. Recent Developments & Impact Analysis, 2025
• 17.4. Product Portfolio Analysis, 2025
• 17.5. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Amgen Inc.
• 18.2. Arthrosi Therapeutics, Inc.
• 18.3. Boehringer Ingelheim International GmbH
• 18.4. GlaxoSmithKline plc
• 18.5. Grifols, S.A.
• 18.6. Horizon Therapeutics plc
• 18.7. InventisBio Co., Ltd.
• 18.8. Ironwood Pharmaceuticals, Inc.
• 18.9. Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
• 18.10. Novartis AG
• 18.11. Olatec Therapeutics, Inc.
• 18.12. Protalix BioTherapeutics, Inc.
• 18.13. Regeneron Pharmaceuticals, Inc.
• 18.14. Sanofi
• 18.15. Selecta Biosciences, Inc.
• 18.16. Shanton Pharma Co., Ltd.
• 18.17. Swedish Orphan Biovitrum AB
• 18.18. Takeda Pharmaceutical Company Limited
• 18.19. TWi Biotechnology, Inc.
• 18.20. XORTX Therapeutics Inc.

19. Key Experts